Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3077791 50 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
In this post hoc analysis we investigated the effects of insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus comparators on cardiovascular (CV) risk markers in participants in the DUAL II (vs. insulin degludec), DUAL V (vs. insulin glargine 100 units/mL) and DUAL VII (vs. basal–bolus therapy) trials, grouped by sex, age (<65 years, ≥65 years) and diabetes duration (<10 years, ≥10 years). Treatment contrasts were in favour of IDegLira in many subgroups for changes from baseline in glycated haemoblogin (DUAL II, DUAL V), body weight (all three trials), systolic blood pressure (BP; all three trials), HDL cholesterol (DUAL VII) and LDL cholesterol (DUAL II, DUAL V). Higher heart rates were seen with IDegLira versus comparators (all three trials) plus significantly higher diastolic BP in men (DUAL V). Differences in treatment effect were seen between sexes in waist circumference (DUAL II), systolic BP (DUAL II, DUAL V) and triglycerides (DUAL VII), and between diabetes durations in LDL cholesterol (DUAL V). In conclusion, IDegLira is associated with a general improvement in CV risk markers compared with basal insulin or basal–bolus therapy after 26 weeks of treatment. © 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Έτος δημοσίευσης:
2019
Συγγραφείς:
Vilsbøll, T.
Blevins, T.C.
Jodar, E.
Poulter, N.
Tentolouris, N.
Ross Agner, B.F.
Lehmann, L.
Leiter, L.A.
Περιοδικό:
Diabetes, Obesity and Metabolism
Εκδότης:
Wiley-Blackwell Publishing Ltd
Τόμος:
21
Αριθμός / τεύχος:
6
Σελίδες:
1506-1512
Λέξεις-κλειδιά:
glycosylated hemoglobin; high density lipoprotein cholesterol; insulin degludec; insulin degludec plus liraglutide; insulin glargine; low density lipoprotein cholesterol; triacylglycerol; antidiabetic agent; insulin degludec; liraglutide; long acting insulin, adult; aged; Article; cardiovascular risk; diabetes control; diastolic blood pressure; disease duration; female; heart rate; human; male; non insulin dependent diabetes mellitus; post hoc analysis; systolic blood pressure; waist circumference; blood pressure; cardiovascular disease; complication; drug combination; middle aged; risk factor, Aged; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Liraglutide; Male; Middle Aged; Risk Factors; Waist Circumference
Επίσημο URL (Εκδότης):
DOI:
10.1111/dom.13675
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.